Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit
15 sept. 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare Conference
30 août 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate Updates
11 août 2022 16h05 HE | Kinnate Biopharma
Phase 1 clinical trial for KIN-2787, the company’s investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate’s China joint ventureU.S. Food and Drug Administration...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
02 août 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
01 juin 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
26 mai 2022 17h00 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates
12 mai 2022 16h05 HE | Kinnate Biopharma
Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248
18 avr. 2022 08h00 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting
08 avr. 2022 16h30 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
28 mars 2022 16h05 HE | Kinnate Biopharma
Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the...